0000000001011744
AUTHOR
Vassilis Georgoulias
State of the art treatment for gastric cancer: future directions
Abstract Surgery remains the primary curative treatment for gastric cancer although the last 40 years has witnessed the increased utilisation of chemotherapy. 5-Fluorouracil (5-FU or F), then more recently cisplatin (C) and their derivatives, have laid the foundations for the use of chemotherapy and their activity has been modulated by combination with other anti-cancer drugs such as epirubicin (E) or leucovorin (folinic acid, LV) to improve the outcome for patients with advanced gastric cancer. In the palliative setting, despite recent efforts to refine and develop cisplatin/5-FU-based combinations and explore their effectiveness in different settings and regimens, the response rate has re…
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients eligible for second-line treatment is scarce. The aim of this study was to assess the prognostic role of a number of routinely collected clinical variables and to provide a summary index to discriminate patients according to probability of survival.Methods: individual data from nine randomised trials of second-line treatment in advanced NSCLC were analysed. Primary end-point was overall survival (OS). Cox model, stratified by trial, was used for multivariate analyses, and a prognostic index was provided and validated according to an internal/external procedure.Results: Out of 1239 patients, 119…